HAYWARD, Calif., Aug. 30, 2016 /PRNewswire/ -- Impax
Laboratories, Inc. (NASDAQ: IPXL) today provided an
update and additional information to patients, physicians and
customers on its epinephrine injection, USP auto-injector, 0.15 mg
and 0.3 mg., the authorized generic of Adrenaclick®.
Epinephrine injection, USP auto-injector (also called
epinephrine auto-injector) is an emergency injection (shot) of
epinephrine used for the treatment of life-threatening allergic
reactions known as anaphylaxis.
"With all the recent news related to epinephrine auto-injection
products, we are increasing our mission to inform patients,
caregivers and the professional community regarding the
availability of this epinephrine auto-injector product," said
Fred Wilkinson, President and Chief
Executive Officer of Impax. "Our epinephrine auto-injector
represents a proven, low-cost treatment for patients in the U.S.
who require the use of epinephrine products."
The auto-injector is conveniently packaged with numbered and
color-coded instructions and is designed for single-dose use by
patients and caregivers in an anaphylactic emergency. It is
available in a package of two injectors and trainers are available
upon request. For more information about the Impax'
epinephrine auto-injector and its $0
co-pay program, please visit: http://epinephrineautoinject.com/ or
call 855-449-4712.
About Epinephrine Injection, USP
Auto-Injector
Epinephrine injection, USP auto-injector (also
called epinephrine auto-injector) is an emergency injection (shot)
of epinephrine used for the treatment of life-threatening allergic
reactions known as anaphylaxis. Before you use the
epinephrine auto-injector, tell your healthcare provider about all
your medical conditions. With numbered and color-coded
instructions, epinephrine auto-injector is designed for single-dose
use by patients and caregivers in an anaphylactic emergency and
does not take the place of emergency medical care. After
using epinephrine auto-injector go to your doctor or emergency room
right away for more medical treatment. For full Prescribing
Information see
http://epinephrineautoinject.com/pdf/Prescribing-Information.pdf.
For more information about epinephrine injection, USP
auto-injector, ask your doctor or call 1-888-894-6528.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995:
To the extent any statements made in this news release contain
information that is not historical; these statements are
forward-looking in nature and express the beliefs and expectations
of management. Such statements are based on current expectations
and involve a number of known and unknown risks and uncertainties
that could cause the Company's future results, performance, or
achievements to differ significantly from the results, performance,
or achievements expressed or implied by such forward-looking
statements. Such risks and uncertainties include, but are not
limited to: fluctuations in revenues and operating income; the
Company's ability to successfully develop and commercialize
pharmaceutical products in a timely manner; reductions or loss of
business with any significant customer; the substantial portion of
the Company's total revenues derived from sales of a limited number
of products; the impact of consolidation of the Company's customer
base; the impact of competition; the Company's ability to sustain
profitability and positive cash flows; any delays or unanticipated
expenses in connection with the operation of the Company's
manufacturing facilities; the effect of foreign economic,
political, legal, and other risks on the Company's operations
abroad; the uncertainty of patent litigation and other legal
proceedings; the increased government scrutiny on the Company's
agreements with brand pharmaceutical companies; product development
risks and the difficulty of predicting FDA filings and approvals;
consumer acceptance and demand for new pharmaceutical products; the
impact of market perceptions of the Company and the safety and
quality of the Company's products; the Company's determinations to
discontinue the manufacture and distribution of certain products;
the Company's ability to achieve returns on its investments in
research and development activities; changes to FDA approval
requirements; the Company's ability to successfully conduct
clinical trials; the Company's reliance on third parties to conduct
clinical trials and testing; the Company's lack of a license
partner for commercialization of NUMIENT™ (IPX066)
outside of the United States;
impact of illegal distribution and sale by third parties of
counterfeits or stolen products; the availability of raw materials
and impact of interruptions in the Company's supply chain; the
Company's policies regarding returns, allowances and chargebacks;
the use of controlled substances in the Company's products; the
effect of current economic conditions on the Company's
industry, business, results of operations and financial condition;
disruptions or failures in the Company's information technology
systems and network infrastructure caused by third party breaches
or other events; the Company's reliance on alliance and
collaboration agreements; the Company's reliance on licenses to
proprietary technologies; the Company's dependence on certain
employees; the Company's ability to comply with legal and
regulatory requirements governing the healthcare industry; the
regulatory environment; the effect of certain provisions in the
Company's government contracts; the Company's ability to protect
its intellectual property; exposure to product liability claims;
risks relating to goodwill and intangibles; changes in tax
regulations; the Company's ability to manage growth, including
through potential acquisitions and investments; the risks
related to the Company's acquisitions of or investments in
technologies, products or businesses; the restrictions imposed by
the Company's credit facility and indenture; the Company's level of
indebtedness and liabilities and the potential impact on cash
flow available for operations; uncertainties involved in the
preparation of the Company's financial statements; the Company's
ability to maintain an effective system of internal control over
financial reporting; the effect of terrorist attacks on the
Company's business; the location of the Company's manufacturing and
research and development facilities near earthquake fault lines;
expansion of social media platforms and other risks described
in the Company's periodic reports filed with the Securities and
Exchange Commission. Forward-looking statements speak only as
to the date on which they are made, and the Company undertakes no
obligation to update publicly or revise any forward-looking
statement, regardless of whether new information becomes available,
future developments occur or otherwise.
About Impax Laboratories, Inc.
Impax Laboratories,
Inc. (Impax) is a specialty pharmaceutical company applying its
formulation expertise and drug delivery technology to the
development of controlled-release and specialty generics in
addition to the development of central nervous system disorder
branded products. Impax markets its generic products through its
Impax Generics division and markets its branded products through
its Impax Specialty Pharma division. Additionally, where
strategically appropriate, Impax develops marketing partnerships to
fully leverage its technology platforms and pursues partnership
opportunities that offer alternative dosage form technologies, such
as injectables, nasal sprays, inhalers, patches, creams and
ointments. For more information, please visit the Company's Web
site at: www.impaxlabs.com.
Company
Contacts:
Mark Donohue
Investor Relations and Corporate Communications
(215)
558-4526
www.impaxlabs.com
Photo -
http://photos.prnewswire.com/prnh/20160829/402452
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/impax-provides-update-on-epinephrine-injection-usp-auto-injector-300319801.html
SOURCE Impax Laboratories, Inc.